Sputnik V COVID is 91.6% Effective Against COVID: The Lancet
Sputnik V showed strong efficacy, immunogenicity and safety results.
Russia's Sputnik V vaccine is 91.6 per cent effective against symptomatic Covid-19, according to The Lancet on Tuesday, 2 February.
In an interim analysis of the randomized, double-blind, placebo-controlled Phase III clinical trial, Sputnik V showed strong efficacy, immunogenicity and safety results. The data was based on the results of 19,866 volunteers.
“The data indicate that the Sputnik V vaccine shows encouraging activity, including in a cohort of participants aged 60 and above. This is one of the first studies to use two different vectors for the two vaccination steps, a strategy designed to maximize the immune response against the COVID-19 antigen. It represents an impressive development and important contribution to the worldwide fight against COVID-19.”Len Seymour, Professor of Gene Therapies in the Department of Oncology at the University of Oxford, UK
Russia is already rolling out the vaccine, which was the world’s first registered vaccine against coronavirus, and India hopes to launch the vaccine in March. The Russian vaccine was globally criticised for its rushed process and lack of transparency, but these results suggest it is indeed safe and efficacious.
The two-dose treatment of Sputnik V was administered 21 days apart.
The efficacy percentage is based on the analysis of 78 confirmed cases of COVID-19 identified in the placebo group (62 cases) and in the vaccine group (16 cases)
Some Key Figures
As per The Lancet’s analysis, Sputnik V has an excellent safety profile:
- Sputnik V provides full protection against severe cases of COVID-19
- Efficacy in the elderly group of 2,144 volunteers over 60 years old was 91.8% - this did not differ statistically from the 18-60 group
- From the cases analysed, over 98% of volunteers developed humoral immune response and 100% cellular immune response.
Where There Any Adverse Events?
Up to 94 per cent of the adverse events were mild and included flu-like syndromes, injection site reactions, headache and asthenia.
There were no serious adverse events confirmed the Independent Data Monitoring Committee. No strong allergies or anaphylactic shock either.
(Subscribe to FIT on Telegram)
Subscribe To Our Daily Newsletter Now.